Your session is about to expire
← Back to Search
Other
Stellate Ganglion Block (SGB) for COVID-19 Acute Respiratory Distress Syndrome (ARDS)
N/A
Waitlist Available
Led By Ali R Rezai, MD
Research Sponsored by West Virginia University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 3 months
Awards & highlights
No Placebo-Only Group
Summary
This trial is testing if a nerve-blocking procedure called Stellate Ganglion Block (SGB) is safe and helpful for patients with severe lung damage from COVID-19. The procedure involves injecting a local anesthetic near neck nerves to reduce inflammation and improve lung function. The goal is to see if this can slow down the worsening of lung injury in these patients. Stellate Ganglion Block (SGB) has been used for various conditions including PTSD, sudden hearing loss, and gastrointestinal function improvement.
Eligible Conditions
- Coronavirus
- Acute Respiratory Distress Syndrome
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 3 months
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~3 months
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Adverse events related to SGB
All Adverse events
Death
Secondary study objectives
Assessment of respiratory/ pulmonary function
Cardiac function
Radiographic criteria
Side effects data
From 2022 Phase 1 & 2 trial • 20 Patients • NCT05445921100%
Horner syndrome
45%
Hoarseness
35%
Globus
25%
Brief lightheadedness
20%
Numbness of the face
20%
Mild shortness of breath
15%
Nasal congestion
15%
Fatigue
15%
Pain at the injection site
5%
Tightness of the back
5%
Weakness of the neck/back
5%
Headache
5%
Palpitations
5%
Weakness of the arm
5%
Arm heaviness
5%
Cough
5%
Bruising of the injection site
5%
Chest heaviness
5%
Tightness of the shoulder
100%
80%
60%
40%
20%
0%
Study treatment Arm
Stellate Ganglion Block
Awards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
1Treatment groups
Experimental Treatment
Group I: Stellate Ganglion Block (SGB)Experimental Treatment1 Intervention
Clinical Stellate ganglion block
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Stellate Ganglion Block
2020
Completed Phase 2
~250
Find a Location
Who is running the clinical trial?
West Virginia UniversityLead Sponsor
185 Previous Clinical Trials
64,768 Total Patients Enrolled
Ali R Rezai, MDPrincipal InvestigatorWest Virginia University
1 Previous Clinical Trials
4 Total Patients Enrolled